DigestRedComo funciona
Red
/
Empresas
Ph
No verificado

Pheast Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
03/08/2026
Web y redes sociales
Finanzas
Industria
Oncología
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Pheast Therapeutics to Host Educational KOL Webinar on Emerging Role of Macrophage Checkpoint Biology for the Treatment of Solid Tumors
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0
21/07/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Pheast Therapeutics Announces Publication in Clinical Cancer Research Demonstrating Robust Anti-Tumor Activity of PHST001
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0
17/03/2026
Biotecnología
Farmacéutica
Salud
Oncología
Eventos
Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0
03/06/2025
Biotecnología
Higiene alimentaria
Salud
Sanidad
Farmacéutica
Oncología
Ciencia
Ir de compras
Medicina - Varios
Industria
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0
14/04/2025
Industria
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
Oncología
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0
18/02/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado laboral
Industria
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0
07/11/2024
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
Fuente
Pheast Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0